Progress on the launch of domestic generic drugs of talazoparib

Talazoparib, as a new type of oral PARP inhibitor, has attracted global attention in the field of tumor treatment such as breast cancer and prostate cancer. Its original drug, developed by Pfizer, mainly induces tumor cell apoptosis by inhibiting DNA damage repair in tumor cells. Compared with other similar PARP inhibitors, talazoparib has higher binding affinity and inhibitory activity in its molecular structure, and is therefore recommended in multiple international guidelines as an important treatment option for cancers related to BRCA mutations.

Currently, the original drug of talazoparib has been approved for marketing in China for the treatment of patients with germline BRCA-mutated and HER2-negative locally advanced or metastatic breast cancer. However, due to the short time it has entered the domestic market, information on the scope of medical insurance reimbursement, price negotiation results, and clinical accessibility are still in the gradual advancement stage. Usually, new targeted drugs will go through a period of clinical use and evaluation before entering the medical insurance catalog. Therefore, their prices may be relatively high in the short term, and patients still have pressure to purchase drugs.

In terms of domestic generic drugs, no domestic company has yet officially obtained marketing approval for generic drugs of talazoparib. Considering the complexity of the drug's molecular synthesis and the fact that patent barriers have not yet fully expired, domestic pharmaceutical companies are actively carrying out relevant research and development and application preparations. Once the patent ban is lifted, the emergence of generic drugs will help reduce the financial burden on patients and improve drug accessibility.

Judging from the laws of the domestic pharmaceutical market, if domestic generic drugs are successfully launched in the future, they will not only have a competitive advantage in price, but may also accelerate medical insurance negotiations and benefit more cancer patients. It is worth noting that as China’s R&D system for innovative drugs and generic drugs continues to improve, more and more targeted drugs are being produced locally. Although the localization process of talazoparib has not yet been implemented, the market potential and clinical demand behind it have been generally optimistic.

Reference materials:https://www.talzenna.com/